Platelet Derived Growth Factor-B and Human Epidermal Growth Factor Receptor-2 Polymorphisms in Gall Bladder Cancer

  • Mishra, Kumudesh (Department of Surgical Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences) ;
  • Behari, Anu (Department of Surgical Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences) ;
  • Kapoor, Vinay Kumar (Department of Surgical Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences) ;
  • Khan, M. Salman (Department of Biosciences, Integral University) ;
  • Prakash, Swayam (Department of Medical Genetics, Sanjay Gandhi Postgraduate Institute of Medical Sciences) ;
  • Agrawal, Suraksha (Department of Surgical Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences)
  • Published : 2015.09.02


Gall bladder cancer (GBC) is a gastro-intestinal cancer with high prevalence among north Indian women. Platelet derived growth factor-B (PDGFB) and human epidermal growth factor receptor-2 (HER2) may play roles in the etiology of GBC through the inflammation-hyperplasia-dysplasia-carcinoma pathway. To study the association of PDGFB and HER2 polymorphisms with risk of GBC, 200 cases and 300 controls were considered. PDGFB +286A>G and +1135A>C polymorphisms were investigated with an amplification refractory mutation system and the HER2 $Ile^{655}Val$ polymorphism by restriction fragment length polymorphism. Significant risk associations for PDGFB +286 GG (OR=5.25) and PDGFB +1135 CC (OR=3.19) genotypes were observed for GBC. Gender wise stratification revealed susceptibility for recessive models of PDGFB +1135A>C (OR=3.00) and HER2 $Ile^{655}Val$ (OR=2.52) polymorphisms among female GBC cases. GBC cases with gall stones were predisposed to homozygous +286 GG and +1135 CC genotypes. Significant risk associations were found for ACIle (OR=1.48), GAVal (OR=1.70), GAIle (OR=2.00) haplotypes with GBC cases and GCIle haplotype with female GBC cases (OR=10.37, P=<0.0001). Pair-wise linkage disequilibrium revealed negative associations among variant alleles. On multi-dimensional reduction analysis, a three factor model revealed significant gene-gene interaction for PDGFB +286A>G, PDGFB +1135A>C and HER2 Ile165Val SNPs with GBC. Protein-protein interaction showed significant association of PDGFB and HER2 with the epidermal growth factor receptor signaling pathway.


  1. Aggarwal S, Parveen F, Faridi RM, et al (2011). Vascular endothelial growth factor gene polymorphisms in North Indian patients with recurrent miscarriages. Reprod Biomed Online, 22, 59-64.
  2. Ben-Ari Z, Tambur AR, Pappo O, et al (2006). Platelet-derived growth factor gene polymorphism in recurrent hepatitis C infection after liver transplantati don. Transplantat, 81, 392-7.
  3. Bravo M, Vasquez R, Rubio H, et al (1991). Production of platelet-derived growth factor by human lung cancer. Respir Med, 85, 479-85.
  4. Cao Y (2005). Opinion: emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis. Nat Rev Cancer, 5, 735-43.
  5. Chung CK, Antoniades HN (1992). Expression of c-sis/platelet-derived growth factor B, insulin-like growth factor I, and transforming growth factor alpha messenger RNAs and their respective receptor messenger RNAs in primary human gastric carcinomas: in vivo studies with in situ hybridization and immunocytochemistry. Cancer Res, 52, 3453-9.
  6. Donnem T, Al-Saad S, Al-Shibli K, Busund LT, Bremnes RM (2010). Co-expression of PDGFB and VEGFR-3 strongly correlates with lymph node metastasis and poor survival in non-small-cell lung cancer. Ann Oncol, 21, 223-31.
  7. Hahn LW, Ritchie MD, Moore JH (2003). Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics, 19, 376-82.
  8. Hamdani NH, Qadri SK, Aggarwalla R, et al (2012). Clinicopathological study of gall bladder carcinoma with special reference to gallstones: our 8-year experience from Eastern India. Asian Pac J Cancer Prev, 13, 5613-7.
  9. Hsing AW, Gao YT, Han TQ, et al (2007). Gallstones and the risk of biliary tract cancer: a population-based study. Br J Cancer, 97, 1577-82.
  10. Kara O, Duman BB, Kara B, et al (2012). Analysis of PTEN, VEGF, HER2 and P53 status in determining colorectal cancerbenefit from bevacizumab therapy. Asian Pac J Cancer Prev, 13, 6397-401.
  11. Karaca H, Deniz K, Berk V, Inanc M, Ozkan M (2012). Association of human epidermal growth factor receptor-2 expression and clinicopathological findings in patients with colorectal cancer. Asian Pac J Cancer Prev, 13, 6221-5.
  12. Kumari N, Kapoor VK, Krishnani N, Kumar K, Baitha DK (2012). Role of C-erbB2 expression in gallbladder cancer. Indian J Pathol Microbiol, 55, 75-9.
  13. Kuraoka K, Matsumura S, Hamai Y, et al (2003). A single nucleotide polymorphism in the transmembrane domain coding region of HER2 is associated with development and malignant phenotype of gastric cancer. Int J Cancer, 107, 593-6.
  14. Li M, Zhang Z, Li X, et al (2014). Whole exome and targeted gene sequencing of gall bladder carcinoma identifies recurrent mutations in the ErBb pathway. Nature Genetics, 46, 872-6.
  15. Marmor MD, Skaria KB, Yarden Y (2004). Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys, 58, 903-13.
  16. Matsumoto S, Yamada Y, Narikiyo M, et al (2007). Prognostic significance of platelet-derived growth factor-BB expression in human esophageal squamous cell carcinomas. Anticancer Res, 27, 2409-14.
  17. McKay JA, Loane JF, Ross VG, et al (2002). C-erbB-2 is not a major factor in the development of colorectal cancer. Br J Cancer, 86, 568-73.
  18. Mishra K, Behari A, Kapoor VK, et al (2013). Vascular endothelial growth factor single nucleotide polymorphism in gall bladder cancer. J Gastroenterol Hepatol, 28, 1678-85.
  19. Muddana V, Park J, Lamb J, et al (2010). Are genetic variants in the platelet-derived growth factor [beta] gene associated with chronic pancreatitis? Pancreas, 39, 1215-9.
  20. Nakajima M, Sawada H, Yamada Y, et al (1999). The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer, 85, 1894-902.<1894::AID-CNCR3>3.0.CO;2-J
  21. Nakazawa K, Dobashi Y, Suzuki S, et al (2005). Amplification and overexpression of c-erbB-2, epidermal growth factor receptor and c-met in biliary tract cancers. J Pathol, 206, 356-65.
  22. National Cancer Registry Programme (2002). Two-year report of the Population Based Cancer Registries, 1997-98. New Delhi: Indian Council of medical research.
  23. Panagiotou I, Georgiannos SN, Tsiambas E, et al (2012). Impact of HER2 and PTEN simultaneous deregulation in non-small cell lung carcinoma: correlation with biological behavior. Asian Pac J Cancer Prev, 13, 6311-8.
  24. Papewalis J, Nikitin AYu, Rajewsky MF (1991). G to A polymorphism at amino acid codon 655 of the human erbB-2/ HER2gene. Nucleic Acids Res, 19, 5452.
  25. Prakash S, Prasad N, Sharma RK, Faridi RM, Agrawal S (2012). Vascular endothelial growth factor gene polymorphisms in North Indian patients with end stage renal disease. Cytokine, 58, 261-6.
  26. Qu K, Liu SN, Chang HL, et al (2012). Gallbladder cancer: a subtype of biliary tract cancer which is a current challenge in China. Asian Pac J Cancer Prev, 13, 1317-20.
  27. Quaye L, Song H, Ramus SJ, et al (2009). Tagging singlenucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer. Br J Cancer, 100, 993-1001.
  28. Rakhshani N, Kalantari E, Bakhti H, Sohrabi MR, Mehrazma M (2014). Evaluation of HER-2/neu overexpression in gastric carcinoma using a tissue microarray. Asian Pac J Cancer Prev, 15, 7597-602.
  29. Randi G, Franceschi S, La Vecchia C (2006). Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer, 118, 1591-602.
  30. Sole X, Guino E, Valls J, Iniesta R, Moreno V (2006). SNPStats: a web tool for the analysis of association studies. Bioinformatics, 22, 1928-9.
  31. Wang L, Habuchi T, Takahashi T, et al (2002). No association between HER2 gene polymorphism at codon 655and a risk of bladder cancer. Int J Cancer, 97, 787-90.
  32. Warde-Farley D, Donaldson SL, Comes O, et al (2010). The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res, 38, 214-20.
  33. Wong FH, Hu CP, Chiu JH, et al (1994). Expression of multiple oncogenes in human esophageal carcinomas. Cancer Invest, 12, 121-31.
  34. Xie D, Shu XO, Deng Z, et al (2000). Population-based, casecontrol study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst, 92, 412-7.
  35. Yamamoto Y, Yamagishi S, Hsu CC, Yamamoto H (1996). Advanced glycation end products-receptor interactions stimulate the growth of human pancreatic cancer cells through the induction of platelet-derived growth factor-B. Biochem Biophys Res Commun, 222, 700-5.
  36. Zahir ST, Tafti HF, Rahmani K (2014). Overexpression of HER- 2/neu in patients with prostatic adenocarcinoma. Asian Pac J Cancer Prev, 15, 6425-8.

Cited by

  1. Randomized-Control Screening Trials to Lower Gall Bladder Cancer Mortality in High Risk Populations vol.17, pp.4, 2016,
  2. Association of HER2 codon 655 polymorphism with ovarian cancer vol.37, pp.6, 2016,